Allarity Therapeutics Inc. (ALLR) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Allarity Therapeutics Inc...

    NASDAQ: ALLR · Real-Time Price · USD
    1.58
    0.04 (2.60%)
    At close: Sep 26, 2025, 3:59 PM
    1.58
    -0.04%
    After-hours: Sep 26, 2025, 07:56 PM EDT

    Allarity Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 9K 37K 120K 106K
    Gross Profit
    		 -9K -37K -120K -106K
    Operating Income
    		 -27.24M -17.93M -34.46M -26.56M
    Interest Income
    		 533K 22K 30K n/a
    Pretax Income
    		 -24.9M -12.62M -17.58M -26.52M
    Net Income
    		 -24.52M -11.9M -16.06M -26.65M
    Selling & General & Admin
    		 11.44M 10.03M 9.96M 12.36M
    Research & Development
    		 6.1M 7.87M 6.93M 14.2M
    Other Expenses
    		 791K n/a n/a n/a
    Operating Expenses
    		 18.33M 17.89M 16.89M 26.56M
    Interest Expense
    		 -653K 498K 223K 499K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 27.24M 17.93M 16.89M 26.56M
    Income Tax Expense
    		 -381K -717K -1.52M 133K
    Shares Outstanding (Basic)
    		 1.58M 1.99M 11.34 7.57
    Shares Outstanding (Diluted)
    		 1.58M 1.99M 11.34 7.57
    EPS (Basic)
    		 -15.56 -0.01 -1.86M -3.52M
    EPS (Diluted)
    		 -15.56 -0.01 -1.86M -3.52M
    EBITDA
    		 -27.24M -12.08M -17.24M -25.91M
    EBIT
    		 -25.55M -12.12M -17.36M -26.02M
    Depreciation & Amortization
    		 -1.69M 37K 120K 106K

    Add to Watchlist